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Abstract
 
Objective
 
The aim of this work was to assess whether psoriasis is associated
with phenotype prevalence and altered activity of haptoglobin (Hpt).
 
Background
 
Hpt is a plasma acute-phase glycoprotein, displaying in humans
three phenotypes. Phenotype prevalence or structure modification of Hpt was
associated with several diseases. The Hpt main function is to bind and carry to
the liver free haemoglobin for degradation and iron recycling. Hpt was recently
found able to bind the apolipoprotein A-I (ApoA-I), thus impairing its
stimulation on the activity of the enzyme lecithin-cholesterol acyl-transferase
(LCAT).
 
Study design
 
Hpt was isolated from patients with psoriasis vulgaris, and its
activity in haemoglobin or ApoA-I binding and LCAT inhibition was compared
with that of normal protein.
 
Methods
 
Two affinity chromatography steps, the first using resin-coupled
haemoglobin and the second anti-Hpt antibodies, were used to purify Hpt. The
protein phenotype was assessed by electrophoresis. Binding experiments were
performed by Enzyme-linked immunosorbent assay with stationary haemo-
globin or ApoA-I, Hpt in solution and anti-Hpt antibodies for detection of bound
Hpt. Standard LCAT assays were carried out in the presence of Hpt purified from
patients or healthy subjects.
 
Results
 
Phenotype prevalence of Hpt in psoriasis was not found. After affinity
chromatography by haemoglobin, albumin and ApoA-I were routinely found
heavily contaminating only Hpt from normal subjects. Isolated Hpt from
patients had lower activity than normal protein in both haemoglobin binding
and LCAT inhibition.
 
Conclusions
 
In psoriasis, Hpt displays some structure modification(s), which
might be associated with the protein function in the disease.
 
Introduction
 
Haptoglobin (Hpt) is a plasma acute phase 
 
α
 
2
 
-sialoglycoprotein
mostly synthesized by the liver.
 
1
 
 Evidence that Hpt is
expressed in other tissues like lung, kidney, skin and heart
is growing up.
 
2
 
 Its production is regulated by cytokines
(interleukin-6, interleukin-1, tumour necrosis factor-
 
α
 
,
etc.) and glucocorticoids.
 
3
 
 Although Hpt is found in the
serum of all mammals, only in humans it is characterized
by molecular heterogeneity depending on genetic
polymorphism and represented by three major phenotypes:
Hpt 1-1, Hpt 2-2, and Hpt 1-2.
 
4
 
 Hpt phenotype prevalence
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appears to be associated to immune response, mainly to
autoimmune and inflammatory disorders.
 
5
 
 Hpt levels
markedly increase during the acute-phase response of
inflammation and in neoplastic diseases, whereas they
decrease in haemolytic and hepatocellular diseases.
 
1
 
 It has
been suggested that Hpt modulates immunological and
inflammatory responses.
 
6–9
 
 The best known biological
function of Hpt is the binding of free haemoglobin (Hb)
for transport to the liver to prevent iron loss and free
radical–mediated renal damage.
 
10
 
 More recently, Hpt was
found able to bind the apolipoprotein A-I (ApoA-I) and
impairing 
 
in vitro
 
 the ApoA-I stimulation on the activity of
the enzyme lecithin-cholesterol acyltransferase (LCAT).
 
11
 
A number of other physiological roles of Hpt were
suggested.
 
12–15
 
 Synthesis of Hpt in the skin was found
interfering with LC function by preventing their func-
tional transformation and activating autologous T cells.
 
16
 
However, it is not clear whether this is an indirect effect
through modulation of antigen-presenting cellular func-
tion, or whether Hpt act directly on T cells. Although the
importance of extrahepatic Hpt synthesis is not yet under-
stood, local Hpt synthesis may provide tissues with local
source of abundant Hpt, which may exhibit differences
in structure and function. As a matter of fact, Hpt structure
modifications of local Hpt isoforms were found associated
with a number of diseases, including vascular disease,
rheumatoid arthritis, endometriosis and ovarian cancer.
 
17–20
 
In all these disorders, the disease-related Hpt isoforms
were detected in plasma, circulating together with normal
hepatic isoforms. The aim of this work was to purify
Hpt from patients with psoriasis vulgaris and ascertain
whether it displays phenotype prevalence in this disease
and different Hb or ApoA-I binding property from normal
protein.
 
Materials and methods
 
Materials
 
Chemicals of the highest purity, bovine serum albumin
(BSA), Hb, cholesterol, cholesteryl linoleate, human Hpt
(mixed phenotypes: Hpt 1-1, Hpt 1-2, Hpt 2-2), rabbit
anti-human Hpt IgG, goat anti-rabbit horseradish
peroxidase (GAR-HRP) IgG, 
 
o
 
-phenylenediamine and
molecular weight markers were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Human ApoA-I and
rabbit anti-human ApoA-I IgG were from Calbiochem
(La Jolla, CA). [1
 
α
 
, 2
 
α
 
-
 
3
 
H] Cholesterol (45 Ci/mmol) was
obtained from Perkin-Elmer (Boston, MA, USA). Hi-
Trap NHS-activated columns (Amersham Biosciences,
Buckinghamshire, UK) and Sil-G plates for thin-layer
chromatography (0.25 mm thickness) of Macherey-Nagel
(Düren, Germany) were used.
 
Subjects and clinical evaluation
 
Patients (
 
n
 
 
 
=
 
 46) with psoriasis vulgaris and control
subjects (
 
n
 
 
 
=
 
 44) matched for age and cardiovascular risk
factors [total cholesterol, high-density lipoprotein (HDL)
and low-density lipoprotein (LDL) cholesterol, smoking
status, blood pressure] were enrolled after informed
consent. The patients had active disease and were not
taking anti-inflammatory drugs. No subject had any
symptom or laboratory finding of kidney, liver or thyroid
dysfunction, infection, diabetes, malignancy, or was
taking drugs affecting plasma lipid or lipoprotein levels.
The present investigation conforms with the principles
outlined in the declaration of Helsinki.
 
Hpt puriﬁcation
 
Venous peripheral blood was drawn into a heparinized
tube, and plasma was obtained by centrifugation (500 
 
×
 
 
 
g
 
;
15 min; 4
 
°
 
C). Hpt purification was done by affinity
chromatography. Hi-Trap NHS-activated resin was used
to bind Hb on the stationary phase, according to the
manufacturer’s instructions. Approximately 10 mg Hb
was coupled with 1 mL of resin. The Hb affinity column
was equilibrated was 10 volumes of PBS (50 m
 
M
 
Na
 
2
 
HPO
 
4
 
/NaH
 
2
 
PO
 
4
 
 pH 7.4) and then loaded with 2 mL of
plasma at 0.2 mL/min. Plasma samples from the different
individuals were separately processed. The column flow
through was loaded again for three times to achieve total
binding of the Hpt isoforms. The Hpt-loaded resin was
extensively washed, to remove unbound material with
PBS at 1 mL/min flow rate. When the effluent absorbance
at 280 nm was no longer detected, Hpt was eluted, at first
with 15 mL of 0.2 
 
M
 
 glycine-HCl at pH 3.5, then with
10 mL of 0.2 
 
M
 
 glycine-HCl at pH 2.8. Fractions of 0.5 mL
were collected into tubes containing 1 
 
M
 
. Tris base in order
to adjust fraction pH and analysed for their absorbance
at 280 nm (
 
A
 
280
 
)
 
 
 
to monitor protein elution. This Hpt
preparation was used to detect the protein phenotype but
was not suitable for assaying the protein activity owing to
the presence of contaminants. In order to isolate Hpt, the
material from chromatography with resin-linked Hb was
processed by a further step of affinity chromatography,
using a small column of anti-Hpt IgG coupled to the
stationary phase. Sample loading, column washing and
protein elution were done as for affinity chromatography
with Hb. The Hpt phenotype was determined as reported
elsewhere.
 
21
 
Electrophoresis and densitometry
 
Electrophoresis in denaturing and reducing condition
was carried out on 1.5-mm-thick slab gel, using the
 Cigliano 
 
et al.
 
Changes of haptoglobin activity in psoriasis
 
© 2007 The Authors
 
419
 
JEADV
 
 2008, 
 
22
 
, 417–425 Journal compilation © 2007 European Academy of Dermatology and Venereology
 
discontinuous system described by Laemmli but with a
separating gel containing 15% or 10% polyacrylamide.
 
22
 
Sample containing 3 to 5 
 
µ
 
g of protein were boiled in the
O’Farrell buffer O, containing sodium dodecylsulphate
and 
 
β
 
-mercaptoethanol, for 5 min before loading on the
gel.
 
23
 
 Molecular weight markers (BSA, 66 kDa; egg albumin,
45 kDa; glyceraldehyde-3-phosphate dehydrogenase, 36 kDa;
carbonic anhydrase, 29 kDa; trypsinogen, 24 kDa; trypsin
inhibitor, 20 kDa; and 
 
α
 
-lactalbumin 14 kDa) were
used to measure the protein electrophoretic mobility.
Protein fractionation was achieved in 1 h at 100 V. Electro-
phoresis in denaturing and non-reducing condition was
done on 6% polyacrylamide gel to separate Hpt isoforms
(fig. 1). In particular, purified Hpt samples (3–5 
 
µ
 
g) were
incubated for 5 min at 37 
 
°
 
C in modified O’Farrell buffer
O (i.e. the buffer prepared without 
 
β
 
-mercaptoethanol)
and then loaded on the gel. Electrophoresis was carried
out for 2 h at 100 V. After electrophoresis, the gel was
fixed in acetic acid/isopropanol/water (10 : 25 : 65, v/v/v)
and stained with Coomassie R-250 (0.05%, w/v, in the
fixing solution) for 2 h at room temperature. Destaining
was accomplished by repeatedly shaking the gel in 50
volumes of acetic acid/water (10 : 90, v/v) until a trans-
parent background was obtained.
Protein electrophoresis patterns were analysed by
densitometry as follows. Digital images of gels were
analysed by the Gel-Pro Analyser software (Media
Cybernetics, Silver Spring, MA). The band intensities
were recorded as peaks on a densitogram. Densitometric
signals were arbitrarily expressed as Integrated Optical
Density (IOD). On the basis of a calibration using known
amounts of standard BSA, it was determined that 1 IOD
corresponds to the intensity of 5 ng of Coomassie-stained
protein.
 
Enzyme-linked immunosorbent assay
 
Purified fractions of Hpt were analysed for their Hpt
concentration by enzyme-linked immunosorbent assay
(ELISA), using anti-Hpt and GAR-HRP IgGs according
to a published procedure.
 
21
 
 Wells treated, omitting the
sample or the primary antibody incubation, were used to
evaluate the colour development background or non-specific
binding of the secondary antibody. The calibration curve
was obtained by assaying the immunoreactivity of 0.1,
0.25, 0.50, 0.75, 1.0, and 2.0 ng of commercial protein
standard. The standard concentration was determined by
a colorimetric assay using purified IgG for calibration.
 
24
 
 In
experiments of Hpt binding to Hb, microtiter plate wells
were coated by incubation with 0.4 
 
µ
 
g of Hb in coat-
ing buffer [7 m
 
M
 
 Na
 
2
 
CO
 
3
 
, 17 m
 
M
 
 NaHCO
 
3
 
, 1.5 m
 
M
 
 NaN
 
3
 
(pH 9.6)]. Then, different amounts of Hpt (0.05, 0.1, 0.2
and 0.3 
 
µ
 
M
 
) in dilution buffer [DB: 0.2% BSA, 20 m
 
M
 
 Tris
(pH 7.3), 130 m
 
M
 
 NaCl, 0.05% Tween 20] were incubated
in the wells for 1.5 h at 37 
 
°
 
C. The binding of Hpt to Hb
was detected by anti-Hpt IgG (1 : 5000), GAR-HRP IgG
(1 : 10 000) and colour development was monitored at
492 nm as previously described.
 
11
 
Calculation of Hpt molarity
 
Because both Hpt 1-2 and Hpt 2-2 are oligomeric proteins,
each displaying a mixture of isoforms with different
number of monomers,
 
21
 
 the protein molarity was expressed
as concentration of monomer [i.e. the structure unit
containing one subunit 
 
β
 
 (40 kDa) and one subunit
 
α
 
 (
 
α
 
1
 
, 8.9 kDa, or 
 
α
 
2
 
, 16 kDa)].
 
1
 
 The monomer can be
considered the functional unit of Hpt because the subunit
 
β
 
 harbours the domains involved in binding Hb
 
25,26
 
 or
ApoA-I.
 
27
 
 Thus, molarity of Hpt 2-2 isoforms, which
contain only 
 
α
 
2
 
β
 
 units assembled in circular molecules,
was expressed as 
 
α
 
2
 
β
 
 molarity, and MW 
 
=
 
 56 kDa was
used for calculation. Differently from Hpt 2-2 isoforms,
those of Hpt 1-2 are linear molecules constituted by
differently long sequences of 
 
α
 
2
 
β
 
 units with 
 
α
 
1
 
β
 
 units
at their ends. Therefore, to calculate for Hpt 1-2 the
monomer molarity (i.e. 
 
α
 
1
 
β
 
 molarity 
 
+
 
 
 
α
 
2
 
β
 
 molarity), the
relative amount of 
 
α
 
2
 
β
 
 and 
 
α
 
1
 
β
 
 in the isoform mixture
isolated from different subjects was determined. In
particular, the Hpt 1-2 subunits were fractionated by
ﬁg. 1 Hpt phenotyping. Hpt, as obtained by afﬁnity chromatography with
Hb coupled to stationary phase, was analysed. Aliquots of 40 µg were
loaded on 6% polyacrylamide gel, and the electrophoresis was carried out
in denaturing but non-reducing conditions. The protein pattern of Hpt 1-1
(lane 1), Hpt 1-2 (lane 2) and Hpt 2-2 (lane 3) was detected by staining with
Coomassie R-250. Right, the molecular mass of different isoforms is
indicated accordingly to previously published data [Cigliano ABB2003].
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electrophoresis in denaturing and reducing conditions,
and the intensities of the Coomassie-stained bands were
measured by densitometry.
 
21
 
 The equations [
 
α
 
1 
 
intensity]
/[
 
α
 
2
 
 intensity] 
 
=
 
 [
 
x
 
 
 
×
 
 8900]/[
 
y
 
 × 16 000] and [average
molecular mass of subunit α] = [x × 8900] + [y × 16 000],
where x (relative amount of α1, expressed in grams) + y
(relative amount of α2, expressed in grams) = 1, were
used to calculate the average molecular mass of α. Such a
value, which was different from different protein samples,
was used to calculate the monomer molarity in Hpt 1-2.
In this work, molecular mass values ranging from 48.9 to
56 kDa were assigned to the monomer, depending on
isoform population present in any purified Hpt 1-2.
LCAT assay
A pool of plasma samples, treated 0.65% with dextran
sulphate (DS; MW = 50 kDa) in 0.2 M CaCl2 to remove
very low density lipoprotein, LDL and HDL, was used as
source of LCAT (DS-treated plasma). The enzyme activity
was measured using a proteoliposome (ApoA-I/lecithin/
cholesterol, 1.5 : 200 : 18, molar contribution) as substrate,
essentially according to published procedures.28,29 In
detail, 8 µL of 50 mg/mL egg lecithin in ethanol were
mixed with 18 µL of 1 mg/mL cholesterol in ethanol,
40 µL of [1,2-3H(N)]-cholesterol (1 µCi/mL) into a glass
vial. The solvent was carefully evaporated under nitrogen
stream at room temperature and to the dried lipids 170 µL
of a suspension medium [85 mM sodium cholate, 150 mM
NaCl, 10 mM Tris–HCl (pH 8)] were added. After vigorous
whirling (3 min, room temperature), the micelle suspension
was incubated (90 min, 37 °C) and repeatedly shaken
every 10 min until clear. Then, 90 µL of 1.21 mg/mL
ApoA-I were added to the lipid suspension, which was
further incubated for 1 h at 37 °C. The resulting
proteoliposome suspension was extensively dialysed
against Tris-buffered saline solution containing EDTA
[TBE: 140 mM NaCl, 1 mM EDTA, 10 mM Tris–HCl (pH 7.3)],
at 4 °C, to remove cholate. The resulting volume was
adjusted to 285 µL using TBE. The reaction mixture (1 mL
final volume) was prepared by putting together 697 µL of
TBE containing 5 mM CaCl2, 83 µL of 6% HSA, and
160 µL of proteoliposome suspension (diluted 1 : 20 in
TBE) into a screw-capped tube and heating at 38 °C for
30 min. The assay was carried out by addition of 2.5 µL of
2 mM β-mercaptoethanol and 4 µL of DS-treated plasma
to 100 µL of reaction mixture, which was rapidly divided
into three aliquots of 32 µL and incubated (1 h, 37 °C).
Aliquots of Hpt were added, when required, to the
reaction mixture before incubation, and the protein
molarity was calculated as above described. The reaction
was stopped by addition of 130 µL of ethanol to each
aliquot. The lipids were extracted in 600 µL of hexane,
containing 10 µg/mL cholesterol and 10 µg/mL cholesteryl
linoleate. After recovering the organic phase, the aqueous
phase was again treated with 500 µL of the extraction
solution (twice), and the three extracts were pooled.
Hexane was removed under nitrogen stream, and the
dried lipids were dissolved in 50 µL of chloroform.
Cholesteryl esters were separated from cholesterol by thin
layer chromatography, using petroleum ether, diethyl
ether, and acetic acid (90 : 30 : 1, v/v/v) as mobile phase.
The lipid spots were visualized under iodine vapour and
recovered for scintillation analysis. The enzyme activity
was measured as nmoles of cholesterol esterified per h per
mL of plasma and expressed as units.
Statistics
The Jack-knifing test was used to predict the number
of patients or healthy subjects sufficient to significantly
assess phenotype prevalence. In detail, Hpt phenotype of
patients or healthy subjects was found, seven groups of
sorting (pick up number = 10, 15, 20, 25, 30, 35 and 40)
were chosen, and 10 drawings per group were done to
calculate means and SD values. The SD values were
plotted vs. the relevant pick up number to obtain trend
curve, equation and r2 for each phenotype. Equations
(r2 > 0.99) were solved for SD = 0, and the subject
number resulted to be sufficient for assessing significance.
Samples in the ELISA and LCAT assays were analysed in
triplicate. The program ‘Graph Pad Prism 3′ (GraphPad
Software, San Diego, CA) was used to perform regression
analysis or t-test.
Results
Hpt phenotype prevalence in psoriasis
Hpt was purified from individual plasma of healthy
donors, or patients with psoriasis. The protein was
positively selected by affinity chromatography, using Hb
coupled to stationary phase. The Hpt phenotype was
assessed by electrophoresis on 6% polyacrylamide gel
(fig. 1). In detail, after electrophoresis, the gel was stained
by Coomassie and analysed for the presence of protein
bands corresponding to Hpt isoforms, which are present in
phenotype 1-1 (86 kDa), 2-2 (149, 199, 249 and 299 kDa),
or 1-2 (86, 136, 185, 235 and 269 kDa). As shown in
Table 1, the phenotype Hpt 1-2 was prevalent in healthy
subjects, according to previous information on European
phenotypic distribution.1 Among the patients, Hpt 1-2
was frequent as Hpt 2-2, and prevalence of either pheno-
type was not assessed. The number of subjects with Hpt
1-1 was too low to appreciate a possible difference in
frequency of this phenotype between patients and controls.
Cigliano et al. Changes of haptoglobin activity in psoriasis
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Hpt preparation and ApoA-I titration
Hpt, as obtained by affinity chromatography with
resin-linked Hb, is often accompanied by small amounts
of two proteins (i.e. albumin and ApoA-I).30 We noted
that the contaminant proteins were mainly present in
preparations of Hpt from normal subjects, whereas only
traces (if any) could be detected by gel electrophoresis and
densitometry in Hpt isolated from patients (fig. 2). Owing
to the relevance of the interaction of Hpt with ApoA-I in
the reverse cholesterol transport, we wondered whe-
ther the observed difference in ApoA-I contamination
between Hpt samples from patients and those from
healthy subjects would depend on different plasma levels
of ApoA-I. Thus ApoA-I was titrated in plasma from both
patients and controls by ELISA (1.108 ± 0.095 µg/mL,
n = 5 and 1.12 ± 0.073 µg/mL, n = 5, respectively), and no
significant difference in ApoA-I concentration between
the two groups was found.
Effect of Hpt from patients or controls on LCAT 
activity
Previous data showed that Hpt, by binding ApoA-I,
inhibits the LCAT enzyme by preventing the ApoA-I-
dependent stimulation of the catalytic activity.11 The
lower contamination of ApoA-I present in Hpt pre-
parations from psoriatic patients, compared with those from
healthy donors, suggests that (some) Hpt isoforms might
be associated with the disease and display differences
in structure from normal isoforms. To support such a hypo-
thesis, the function of normal and disease-associated Hpt
was tested in the LCAT assay. Four separated samples
of Hpt (two Hpt 1-2 and two Hpt 2-2) from Hb-affinity
chromatography of plasma from patients were processed
by affinity chromatography with antihuman Hpt, as
described in the method section, in order to obtain Hpt
free of contaminants. The protein purity was over 98%,
as evaluated by gel electrophoresis (data not shown). A
pool of two Hpt 1-2 and two Hpt 2-2 from healthy donors
was prepared and used as control. Aliquots of the two
different pools were mixed with DS-treated plasma, used
as LCAT source, and proteoliposomes containing ApoA-I
and labelled cholesterol. The final Hpt concentration in
the assay mixture was 0.5 or 2 µM Hpt. After incubation,
inhibition of the enzyme activity by normal Hpt was
clearly detected at both concentration used, as expected,
whereas it was significant but lower than normal when the
enzyme assay was carried out with 2 µM Hpt from patients
(fig. 3). The difference between the two Hpt pools in
inhibiting LCAT suggests that the protein purified from
Table 1 Phenotype prevalence of Hpt in psoriasis
Hpt phenotype Patients (n = 46) Controls (n = 44)
1-1 3 2
1-2 22 24
2-2 21 18
ﬁg. 2 Densitometric analysis of Hpt prepared by Hb afﬁnity chromatography
from plasma of patients or healthy subjects. Samples of Hpt, obtained by
afﬁnity chromatography with Hb coupled to Sepharose, were processed by
electrophoresis on 15% polyacrylamide gel in denaturing and reducing
conditions. After staining with Coomassie R-250 and extensive destaining
in acetic acid/water (10 : 90, v/v), digital images were taken by a scanner
with adapter transparency unit for positive ﬁlm, at resolution of 600 pixels
per inch. The images were analysed by the software Gel-Pro, which con-
verted the band intensities in optical densities. Densitograms represent
changes of optical density as function of the electrophoretic migration.
Typical densitograms of samples from patient (a) and healthy subject
(b). The electrophoretic mobility of albumin, ApoA-I, and the Hpt chains α
and β is indicated. Images of protein electrophoretic fractionation used for
densitometry (bottom). Migration toward cathode is expressed as Rf.
Changes of haptoglobin activity in psoriasis Cigliano et al.
422 © 2007 The Authors
JEADV 2008, 22, 417–425 Journal compilation © 2007 European Academy of Dermatology and Venereology
patients has not the same structure of normal protein.
This difference might depend on lower ability of Hpt from
patients to limit ApoA-I stimulation of stimulating LCAT
activity.
Binding of Hpt to ApoA-I or Hb
Differences in Hpt preparation by affinity chromatography
with Hb might underlie different affinity of Hpt for
ApoA-I or Hb. Therefore, Hpt was prepared, free of
contaminants, from patients with psoriasis (n = 4; two
with Hpt 1-2 and two with Hpt 2-2) and tested for its
activity of binding ApoA-I or Hb. Such an activity was
compared with that of Hpt isolated from healthy donors
(n = 4; two with Hpt 1-2 and two with Hpt 2-2). The wells
of a microtiter plate were coated with ApoA-I or Hb and
incubated with different amounts of Hpt (0.03, 0.1, 0.2
and 0.3 µM). Unbound Hpt was removed by extensive
washing, and the complexes of Hpt with ApoA-I or Hb
were targeted by rabbit anti-Hpt antibodies, which were
on turn detected by peroxidase-linked goat anti-rabbit
antibodies with o-phenylenediamine and hydrogen
peroxide. No significant difference in ApoA-I binding
between Hpt from patients and that from controls, at any
used concentration in the assay, was detected. Conversely,
the results indicate Hpt from normal subjects bound Hb
more efficiently than that from patients (fig. 4). In parti-
cular, significant differences were found for samples with
0.1, 0.2 or 0.3 µM Hpt (P < 0.001).
Discussion
The Hpt polymorphism in several diseases was reviewed,
but information on phenotype prevalence in psoriasis
was not provided.1,31–33 In this study, data on decreased
frequency of the Hpt 1-1 phenotype in psoriasis are
reported. Prevalence of Hpt 2-2 isoforms was expected in
psoriasis because they stimulate angiogenesis, a well-
known phenomenon associated with the disease, more
than isoforms of the other two phenotypes.14 Prevalence
of Hpt 2-2 was found in several diseases, and this
phenotype was recognized as risk factor for cardiovascular
diseases.1,31–33 Biochemical mechanisms underlying the
atherogenic properties of Hpt were suggested,34–36 but
molecular evidence on why Hpt 2-2 associates to higher
risk than Hpt 1-1 or Hpt 1-2 is lacking to date. Psoriasis has
been associated with abnormal plasma lipid metabolism
and with high frequency of cardiovascular events.37–44
ﬁg. 3 Inhibition of LCAT activity by Hpt from patients or healthy subjects.
The LCAT activity was assayed by incubating a pool of DS-treated plasma
with a standard reaction mixture, containing a proteoliposome (ApoA-I:
lecithin: 3H-cholesterol, 1.5 : 200 : 18 molar ratio) as substrate. The enzyme
activity was measured in the presence of Hpt (0.5 or 2 µM), puriﬁed from
patients or healthy subjects, and pooled. Pools with equimolar amounts of
Hpt (two Hpt 1-2 samples and two Hpt 2-2 samples) were used. A control
assay was performed without Hpt. The LCAT activity was expressed as
nanomoles of cholesterol incorporated per hour per ml of plasma. The
samples were analysed in triplicate. Columns, means; bars, SE. The enzyme
activity, as measured in the absence of Hpt (white column), was signiﬁcantly
different from that in the presence of both 0.5 or 2 µM Hpt of healthy
subjects and 0.5 µM Hpt from patients (P < 0.001). Differences between 0.5
and 2 µM samples from the same pool and between the two pools at either
concentration were also signiﬁcant (P < 0.001).
ﬁg. 4 Binding of Hpt from patients or healthy subjects to Hb.
Pools with equimolar amounts of puriﬁed Hpt (two Hpt 1-2 samples and two
Hpt 2-2 samples) were prepared. Wells of a microtiter plate were coated
with Hb, and incubated with different amounts of pooled Hpt from patients
(full circles) or healthy subjects (open circles). Anti-Hpt rabbit were used to
bind the formed Hpt–Hb complexes. Following incubation with GAR-HRP
and o-phenylenediamine in the presence of H2O2, the complexes were
detected by measuring the solution absorbance at 492 nm. The samples
were analysed in triplicate. Points, means; bars, SE. Values at 0.1, 0.2 and
0.3 µM Hpt are signiﬁcantly different (P < 0.001).
Cigliano et al. Changes of haptoglobin activity in psoriasis
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This prevalence of cardiovascular events seems to be
related to the severity of psoriasis, considering that it
occurs much more frequently in patients presenting large
areas of the body affected with psoriasis lesions.45
However, we did not found prevalence of Hpt 2-2 in
psoriasis. Therefore, Hpt phenotype prevalence does not
represent a link between psoriasis and cardiovascular
diseases. Abnormal plasma lipid metabolism, in the
onset and progression of cardiovascular diseases, mostly
depends on poor reverse cholesterol transport. In this
process, ApoA-I stimulates cholesterol efflux from peri-
pheral cells and activates LCAT to synthesize cholesteryl
esters, which are then embedded into HDL for transport to
liver. Hpt binds ApoA-I, thus impairing the apolipoprotein
stimulation on the enzyme activity.11 Our results show
that Hpt from patients with psoriasis inhibits cholesterol
esterification less than normal Hpt. This means that
some disease-associated difference in Hpt structure, not
dependent on the protein phenotype, might play a role
in the regulation of the LCAT activity. We cannot exclude
that some difference in LCAT activity between patients
and controls might be observed in vivo, depending on
disease-associated function alteration of ApoA-I, LCAT or
lipids. Oxidative stress, known to occur in inflammation,
might actually be responsible of structure and function
modifications of all these molecules. However, the
results obtained in our experiment of LCAT stimulation
in vitro clearly indicate that at least the Hpt alteration affects
the enzyme activity. In fact, in this experiment, Hpt
was the only variable between patients and controls.
Here we provide evidence that, in psoriasis, plasma
contains Hpt isoforms different from those circulating in
normal conditions. In particular, differences in binding of
albumin, ApoA-I and Hb were observed. Such function
differences seem not to depend on the Hpt phenotype
because both Hpt 1-2 and Hpt 2-2 isoforms from patients
displayed lower binding activity. Poor information is
available on the interaction of Hpt with albumin, and the
significance of such an interaction is not clear.46 It is
possible that albumin binds Hpt to prevent degradation or
aggregate formation of this protein. It cannot be excluded
that albumin does not bind Hpt but interacts with ApoA-I.
In this case, the affinity chromatography would capture
ApoA-I–bound albumin, and a role for albumin could be
envisaged according to previously published data, which
showed albumin requirement for optimal ApoA-I
stimulation on the LCAT activity.47 As a matter of fact, Hpt
from patients displayed lower activity in the LCAT assay as
abovementioned. This means that, in the assay, Hpt binding
to ApoA-I was limited, as expected if albumin would
be required for stabilizing the Hpt-ApoA-I complex.
Therefore, albumin, as binding normal Hpt better than
that present in the patient plasma, would be responsible
of the different amounts of ApoA-I selected by affinity
chromatography of samples from patients or controls.
However, the finding of higher amounts of albumin in Hpt
preparations from healthy subjects than in those from
patients suggests that Hpt with structure changes is pre-
sent in psoriasis. Further evidence on psoriasis-associated
isoforms of Hpt was gained by Hb or ApoA-I binding
experiments. Our data indicate that Hpt from patients
binds Hb less efficiently than Hpt from controls, whereas
no difference in binding purified ApoA-I was observed.
The Hpt-linked glycan chains were shown to be involved
in the formation of the Hpt-Hb complex,48 and changes in
these glycan structures were previously found in diseases
associated to inflammatory conditions.49–51 It is therefore
conceivable that Hpt, in psoriasis, might expose glycans
altered in their structure and function in Hb binding.
Further glycosylation analysis of Hpt from psoriasis is
required to support this hypothesis. Hpt glycan or amino
acid domains involved in the Hb binding do not participate
in the ApoA-I binding.11,52 It remains to be discussed why
disease-associated Hpt isoforms would bind ApoA-I in the
LCAT assay less than normal Hpt, whereas no difference
between patients and controls was observed by ELISA in
this binding. A possible explanation is that albumin might
contribute to stabilize the interaction between Hpt and
ApoA-I in the enzyme assay, whereas its effect might be
poor (if any) in ELISA conditions.
In conclusion, we provide here evidence that Hpt, in
psoriasis, displays structure modification(s) that might
impair the protein function in Hb binding and LCAT
regulation. Structure analysis of Hpt isoforms in psoriasis
and normal conditions are in progress to validate our
hypothesis.
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